Rhabdomyosarcoma - Pediatric Clinical Trial (05.10.029T)

COG ARST0331: Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma

Protocol ID

05.10.029T

Protocol Description

The standard treatment for rhabdomyosarcoma consists of chemotherapy, surgery, and or radiation therapy. This study is being done to find out the most effective treatment with the least amount of therapy that will still cure subjects with low risk rhabdomyosarcoma.  We want to know this because although chemotherapy and radiation therapy can cure low-risk rhabdomyosarcoma, they can also have effects on subjects later in life (late effects).  Late effects can include slowing of growth in children, inability to have children (sterility), and causing another cancer to develop.

Eligibility Criteria

Children and adolescents with rhabdomyosarcoma

Primary Investigator(s)

  • Arlene Redner, MD

Contact Information

Christine Grabowski, CCRP
(718) 470-3401
grabowsk@lij.edu

Last Update

November 13, 2009
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Children's Health:
top